FY2025 EPS Estimates for Korro Bio Raised by William Blair

Korro Bio, Inc. (NASDAQ:KRRO) – Analysts at William Blair increased their FY2025 earnings per share (EPS) estimates for shares of Korro Bio in a research report issued on Thursday, November 13th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($9.26) for the year, up from their prior estimate of ($11.21). William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio’s Q4 2025 earnings at ($2.10) EPS, Q1 2026 earnings at ($1.84) EPS, Q2 2026 earnings at ($1.79) EPS, Q3 2026 earnings at ($1.78) EPS, Q4 2026 earnings at ($1.78) EPS and FY2026 earnings at ($7.18) EPS.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.92) EPS for the quarter, topping analysts’ consensus estimates of ($2.61) by $0.69. The company had revenue of $1.09 million during the quarter, compared to analyst estimates of $0.41 million. Korro Bio had a negative return on equity of 68.87% and a negative net margin of 1,199.53%.

Several other equities analysts have also recently issued reports on KRRO. Piper Sandler cut shares of Korro Bio from an “overweight” rating to a “neutral” rating and set a $11.00 price target on the stock. in a research report on Thursday, November 13th. Chardan Capital reiterated a “neutral” rating on shares of Korro Bio in a report on Thursday, November 13th. Wall Street Zen raised Korro Bio from a “sell” rating to a “hold” rating in a research report on Saturday. Jones Trading lowered Korro Bio from a “buy” rating to a “hold” rating in a research report on Friday, November 14th. Finally, Cantor Fitzgerald cut Korro Bio from an “overweight” rating to a “neutral” rating in a research note on Thursday, November 13th. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Korro Bio currently has an average rating of “Hold” and an average target price of $76.00.

Korro Bio Trading Up 1.1%

Shares of NASDAQ KRRO opened at $6.22 on Monday. The firm has a fifty day simple moving average of $36.58 and a two-hundred day simple moving average of $23.28. Korro Bio has a 12 month low of $5.70 and a 12 month high of $56.69. The firm has a market capitalization of $58.59 million, a PE ratio of -0.66 and a beta of 2.94.

Hedge Funds Weigh In On Korro Bio

Several institutional investors and hedge funds have recently modified their holdings of the stock. TCG Crossover Management LLC bought a new position in Korro Bio in the 3rd quarter worth about $19,937,000. XTX Topco Ltd bought a new position in shares of Korro Bio in the third quarter worth approximately $2,085,000. Polar Capital Holdings Plc grew its holdings in shares of Korro Bio by 5.9% during the third quarter. Polar Capital Holdings Plc now owns 264,694 shares of the company’s stock valued at $12,676,000 after buying an additional 14,694 shares during the last quarter. Millennium Management LLC increased its position in shares of Korro Bio by 1.8% during the third quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after acquiring an additional 4,650 shares in the last quarter. Finally, Algert Global LLC bought a new position in Korro Bio in the 3rd quarter valued at approximately $340,000. 13.18% of the stock is currently owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).